10
Mar
2022
Aiming High, With a Team
Climbing Mt. Everest changed my life. The world’s highest mountain required digging deep — physically, mentally, emotionally. That was four years ago. That original climb was a success, raising $340,000 for cancer research at the Fred Hutchinson Cancer Research Center. But what came next meant more. The climb opened my mind to new ways of making a contribution, in addition... Read More
3
Mar
2022
Biotech Takes a Stand
Not long ago, biotech leaders steered clear of commenting on the issues of the day. Politics was limited to certain vested interests like drug pricing, science funding, and FDA regulation. Then came COVID-19 and the racial justice reckoning. Staring these terrible things in the face, people began to think more about their roles in the workplace, and in the community.... Read More
2
Mar
2022
Rondo Raises $67M to Make Bispecific T-cell Engagers for Solid Tumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Feb
2022
Making Clinical Trials More Diverse: Michele Andrasik on The Long Run
Today’s guest on The Long Run is Michele Andrasik. I’m excited to have Michele on the show to talk about an undercovered aspect of the scientific enterprise. Michele is the director of social and behavioral science and community engagement for the HIV Vaccine Trials Network, and COVID-19 Prevention Network. She’s based in Seattle at the Fred Hutchinson Cancer Research Center,... Read More
17
Feb
2022
The Unsung Community Heroes Who Make Biotech Thrive
Every thriving biotech hub can trace its origins to one or two outstanding scientific institutions. But every thriving region can also trace some of its success back to community leaders. These are people who attend boring night meetings. They aren’t household names. They’re fine with that. These people were especially common in America after World War II. They laid down... Read More
14
Feb
2022
Rethinking the Cell Therapy Business: Derrell Porter of Cellevolve on The Long Run
Today’s guest on The Long Run is Derrell Porter. Derrell is the founder and CEO of San Francisco-based Cellevolve. This is a different kind of biotech startup. Most startups are all about the R&D. Traditionally, many haven’t built up commercial capabilities in the early days for one big reason — they don’t have anything to sell. They have tended to... Read More
10
Feb
2022
Biotech’s Future off The Beaten Path
The future of biotech isn’t limited to a few square miles in Cambridge, Mass. and South San Francisco. Biotech is starting to spread its wings in minor league towns. That’s good news. It’s also necessary for the industry to grow and continue to better integrate into the wider world. Let’s look at an example close to my home in Seattle.... Read More
9
Feb
2022
Seismic Gets $101M to Use Machine Learning for Autoimmune Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
3
Feb
2022
The World Waits for Novavax, and an FDA Commissioner
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2022
TR’s 7th Anniversary: Thank You
Timmerman Report is 7 years old today. On Feb. 2, 2015, I rode my bike to the office on a wet Seattle morning and turned on the lights. I thought there was a need for clear, probing, contextual biotech journalism. It was a leap of faith, like any entrepreneurial venture. I couldn’t have predicted 90 percent of what came next.... Read More
1
Feb
2022
Targeting Integrins With Small Molecules: Praveen Tipirneni on The Long Run
Today’s guest on The Long Run is Praveen Tipirneni. Praveen is the CEO of Waltham, Mass.-based Morphic Therapeutic. Morphic Therapeutic is developing oral small molecule drugs aimed at integrin targets. There’s some fascinating biology and computational technology underpinning this work, which I discussed a couple years ago on The Long Run with Morphic scientific founder Tim Springer. Just to review... Read More
31
Jan
2022
Gandeeva Raises $40m For Fast Cryo-EM Enabled Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jan
2022
A Small Step on Drug Pricing
Mark Cuban, the billionaire-turned-reality TV star, made news this week with the Mark Cuban Cost Plus Drug Company. Cuban has been saying for a while that he wants to stick it to the man. The biopharma man. “I could make a fortune from this,” Cuban told Texas Monthly in September. “But I won’t. I’ve got enough money. I’d rather f—... Read More
27
Jan
2022
Simcha, Backed by SR One, Raises $40m to Inject New Life Into IL-18 for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jan
2022
Reflecting on MLK and Science in Society
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Jan
2022
ImmPACT Bio, with Bispecific CAR-T Showing Durable CRs, Raises $111m Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jan
2022
The Biogen Debacle Continues
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jan
2022
Antibody Engineering & Company Building: Bassil Dahiyat on The Long Run
Today’s guest on The Long Run is Bassil Dahiyat. Bassil is the CEO of Monrovia, Calif.-based Xencor. He’s been on a true Long Run. Bassil co-founded Xencor in 1997 after getting his PhD in chemistry at Caltech. He’s been through a lot of ups and downs in the biotech markets, and taken the company through a couple big strategic shifts.... Read More
6
Jan
2022
Biotech’s Candle Burns Bright in the Dark
Earlier this week, in need of an afternoon break, I went for a 15-minute walk to the local branch of the Seattle Public Library. With KN95 mask snugly in place, I walked in, picked up my book on hold, and walked out. Two minutes, tops. No lingering these days. At home, I flipped open Carl Sagan’s 1996 manifesto, “The Demon-Haunted... Read More
23
Dec
2021
Pfizer, Merck Get COVID Drugs OK’d, Sanofi Buys Amunix, and a New PCSK9 Contender
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.